CLINICAL_TRIALS trial_result · 2025-09-11

Clinical Trial Update: A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy [Phase 3]

A Phase 3 trial evaluating SEL-212 in patients with gout refractory to conventional therapy has completed. Results were posted on 2025-09-11.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Swedish Orphan Biovitrum | Conditions: Chronic Gout | Phase 3 | Status: COMPLETED | Results posted: 2025-09-11